Skip to main content

Combination chemotherapy or chemo-immunotherapy (if HER2 positive), is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0 or stage IB - III hormone receptor negative breast cancer

CBE ID
0559
1.4 Project
Cancer
Endorsed
Endorsement Status
Endorsement Removed
1.1 New or Maintenance
Maintenance
E&M Cycle
Spring 2020
Is Under Review
No
1.3 Measure Description

Percentage of female patients, age >= 18 and < 70 at diagnosis, who have their first diagnosis of cancer (epithelial malignancy), at AJCC stage T1cN0M0 or Stage IB - IIIC, whose primary tumor is of the breast, and progesterone and estrogen receptor negative is recommended or administered multi-agent chemotherapy within 4 months (120 days) of diagnosis

    • 1.14 Numerator

      Combination chemotherapy or chemo-immunotherapy (if HER2 positive), is recommended or administered within 4 months (120 days) of diagnosis

    • 1.15 Denominator

      Include if all of the following characteristics are identified:
      Women
      Age 18-69 at time of diagnosis
      Known or assumed first or only cancer diagnosis
      Epithelial malignancy only
      Primary tumors of the breast
      Invasive tumors
      Surgical procedure of primary site
      AJCC T1cN0M0, or AJCC Stage IB to IIIC
      Primary tumor is estrogen receptor negative and progesterone receptor negative
      All or part of first course of treatment performed at the reporting facility
      Known to be alive within 4 months (120 days) of diagnosis

    • Exclusions

      Exclude, if any of the following characteristics are identified:
      Men
      Age < 18 and >= 70
      Not the first or only cancer diagnosis
      Tumor not originating in the breast
      Non-epithelial malignancies, exclude 8200 - adenoid cystic carcinoma and rare tumors (8940 - Mixed tumor, malignant, NOS; 8950 - Mullerian mixed tumor; 8980 – Carcinosarcoma; 8981 - Carcinosarcoma, embryonal)
      Non-invasive tumors
      ER positive
      PR positive
      Evidence of in situ or metastatic disease
      None of 1st course therapy performed at reporting facility
      No surgical procedure of the primary site
      Died within 4 months (120 days) of diagnosis
      Participation in a clinical trial which directly impacts the delivery of the standard of care
      Not AJCC T1cN0M0 or not AJCC Stage IB-IIIC

    • Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Cancer Spring Cycle 2020
      Initial Endorsement
      Last Updated
      Removal Date